EVIDENCE LIBRARY
Gelsemine Receptor Study Found Inhibition Outside the Conventional Benzodiazepine Binding Site
A laboratory study found negative modulation of GABA-A currents by gelsemine. Its receptor effects differed from assuming a plant anxiolytic acts like a benzodiazepine.
A laboratory study found negative modulation of GABA-A currents by gelsemine. Its receptor effects differed from assuming a plant anxiolytic acts like a benzodiazepine.
The recordings
Researchers used recombinant receptors and cortical neurons to measure gelsemine effects. The compound inhibited agonist-evoked currents and reduced the frequency of inhibitory synaptic events.
The functional inhibition was not associated with the conventional benzodiazepine binding site. The authors separated these observations from behavioral claims made in earlier experimental literature.
Mechanistic precision matters
A plant-derived compound and a prescribed benzodiazepine can affect related systems through different sites and directions. A shared broad label does not establish interchangeable anxiolysis or safety.
Cellular current changes do not directly measure human benefit, toxicity thresholds, or interactions. The paper supports a potential contribution to toxicity and additional mechanistic questions. It cannot establish a safe clinical plant preparation or assign diazepam-equivalent potency from receptor-system overlap alone.
Source paper
Original analysis of the supplied journal article, identified as PMC9887029.